Tesorx Pharma LLC, of San Francisco, and Aska Pharmaceutical Co. Ltd., of Tokyo, said, following a recently completed pharmacokinetic study, they will start preparing for an upcoming phase I/IIa trial of Tesorx's oral testosterone product, TSX-011, expected to be conducted in the U.S. and to include Japanese patients to expedite development in both regions.